Potential adverse effects of discontinuing psychotropic drugs: Part 1: Adrenergic, cholinergic, and histamine drugs

Journal of Psychosocial Nursing and Mental Health Services

Volumn 48, Issue 6, 2010, Pages 11-14

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954005515     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20100506-01     Document Type: Article

References (6)

1. Brunton, L.L., Lazo, J.S., Parker, K.L., Buxton, I.L.O., & Blumenthal, D. (Eds.). (2006). Goodman & Oilman's the pharmacological basis of therapeutics (11th ed.). New York: McGraw-Hill.
2. Matsuda, T.M., Makiguchi, K., & Sugano, K. (1981). Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. Journal of Nervous and Mental Disease, 169, 324-327.
3. Noback, C.R., Strominger, N.L., & De-marest, R.J. (1996). The human nervous system: Structure and function (5th ed.). Philadelphia: Williams & Wilkins.
4. Sadock, B.J., Sadock, V.A., & Sussman, N. (2006). Kaplan & Sadock's pocket handbook of psychiatric drug treatment (4th ed.). Philadelphia: Lippincott Williams & Wilkins.
5. Schatzberg, A.F., Cole, J.O., & DeBattista, C. (2007). Manual of clinical psycho-pharmacology (6th ed.). Arlington, VA: American Psychiatric Publishing.
6. Spivak, B., Gonen, N., Mester, R., Aver-buch, E., Adlersberg, S., & Weizman, A. (1996). Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. International Clinical Psychopharmacology, 11, 207-209.